XBIO Stock Analysis: Buy, Sell, or Hold?
XBIO - Xenetic Biosciences, Inc.
$3.00
-0.13 (-4.31%)
▼
5d:
-4.62%
30d:
+12.17%
90d:
+20.23%
BUY
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 12, 2026
12d
Get Alerted When XBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XBIO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: XBIO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: XBIO is currently trading at $3.00, which is considered fair relative to its 30-day fair value range of $2.86 to $3.31.
Technical Outlook: Technically, XBIO is in a strong uptrend. The price is currently testing key support at $3.02. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $40.00 (+1178.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XBIO is in a strong uptrend. The price is currently testing key support at $3.02. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $40.00 (+1178.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.86 -
$3.31
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 1178.0% below Wall St target ($40.00)
Trading Range Analysis
30-Day Trading Range
$2.86 -
$3.31
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.02
Resistance Level
$3.68
Current Trend
Strong Uptrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.21
Wall Street Target
$40.00
(+1178.0%)
Revenue Growth (YoY)
18.1%
Profit Margin
-90.1%
Share & Embed Analysis
Last updated: April 29, 2026 10:57 AM ET
Data refreshes hourly during market hours. Next update: 11:57 AM
Data refreshes hourly during market hours. Next update: 11:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 60 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 53 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$298 | 58 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 53 HOLD |
